| Advent
International Advent International is one of the world’s largest private equity firms with $6 billion in cumulative capital raised* and offices in 13 countries. We are unique. No other private equity firm has our combination of industry expertise, international resources and local market knowledge. Since our founding in 1984, we have invested in over 500 companies in 35 countries and have helped businesses raise $10 billion through public equity and debt offerings. These include 128 IPOs on major stock exchanges worldwide. We apply our wealth of experience, resources and expertise to help build businesses of significant value around the globe. |
| Advanced
Technology Ventures Founded in 1979, Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm with more than $1.5 billion in capital under management. We work closely with entrepreneurial teams in several technology markets, including communications, IT infrastructure, software and services, and healthcare technologies, to build emerging-growth business ventures into market leaders. With more than 20 years of experience, ATV has a proven track record of success in helping to build strong, sustainable business enterprises. What Sets ATV Apart:
Successful Track Records: Over the years, ATV has a proven history in supporting over 30 companies from inception to IPO or acquisition, representing billions of dollars in market value. Examples include Accord Networks, Actel, Berkeley Networks, Credence Systems, Cytyc, DataSage (Vignette), Docent, Epigram (Broadcom), Novoste, Seagull Software and WebLine Communications (Cisco). |
| AstraZeneca
Pharmaceuticals AstraZeneca (NYSE:AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies with worldwide sales in 2001 totalling $16.5 billion and an operating profit of $4.2 billion. AstraZeneca is committed to building on this success, using its leading position in many important areas of medicine to make a difference to the lives of patients and the healthcare professionals who treat them. Headquartered in the UK, with R&D headquarters in Sweden and a strong presence in the key US market, AstraZeneca sells in over 100 countries, manufactures in 20 and has major research centres in 5. It employs over 54,000 people worldwide and values the diversity of skills and abilities that they bring to the business. AstraZeneca's Research
and Development Organization |
| Atlas
Venture Atlas Venture is the leading international early-stage venture capital firm, investing in communications, information technology and life sciences companies. With investing offices in Boston, London, Munich and Paris, Atlas Venture divides its investments between the United States and Europe. Founded in 1980, Atlas Venture has organized six international funds, and currently manages $2.1 billion in committed capital. The Atlas Venture investment team is comprised of seasoned operating executives and career venture capitalists who have been deeply involved in the formation and development of more than 300 companies worldwide. For more information about Atlas Venture, go to www.atlasventure.com. |
| BankInvest
Bio Venture BankInvest was established as a mutual fund in 1969 by a number of local and regional banks, and today's owners represent a total balance of more than 35bn euros. With more than 30 years' experience as an asset management company and with more than 100,000 unit holders, institutional investors and corporations as clients, BankInvest is at present Denmark's third largest mutual fund manager and advisor. In June 2001, BankInvest's assets under management amounted to approximately 5bn euros, and these continue to grow extremely strongly. BankInvest manages portfolios of both bonds and equities. By using a selective investment strategy, BankInvest manages portfolios with focus on geographic areas as well as sector-specific portfolios. It is particularly within the fields of complex
investments, e.g. biotechnology, information technology and emerging
markets, that BankInvest distinguishes itself as an internationally
leading asset management group. |
| Bio
Fund Management Oy Ltd Bio Fund Management Oy Ltd is one of the leading biotech VC companies in Europe. The company was founded by Dr. Kalevi Kurkijärvi and Mr. Seppo Mäkinen in 1997. Bio Fund solely invests in life science companies. At present it has EUR 185 million under management through three venture capital funds. The main sectors of BioFund include pharmaceuticals and therapies, medical technologies, nutraceuticals, and environmental technologies. Bio Funds recent portfolio consists of 40 companies located in 8 different countries and the number of exited companies so far is slightly below 10. BioFund’s geographical scope focuses mainly in Europe, the Nordic Countries as home market. BioFund is headquartered in Helsinki, Finland and has an office in Turku, Finland. A subsidiary was established at the end of 2001 in Copenhagen, Denmark. Fifteen finance and life science professionals are working in BioFund. The core of BioFund’s investment philosophy is to invest in companies where value can be added through BioFund’s own expertise and network together with the professionals in portfolio companies. BioFund invests mainly in European life sciences companies in their growth phase. Typical size of investments varies EUR 3-8 millions. www.biofund.fi : e-mail: biofund@biofund.fi |
|
Burrill & Company Profile to follow shortly |
| CDP
Capital Technology Ventures Founded in 1995 as a subsidiary of the Caisse de dépôt et placement du Québec (CDP), CDP Capital - Technology Ventures (formerly CDP Sofinov), is a technology venture capital (VC) firm with an established presence in North America and, more recently, in Europe. CDP Capital - Technology Ventures assets under management have a market value of CDN$1.6 billion. Since its inception, it has invested in more than 160 privately owned technology companies in the following investment sectors: Biotechnology and Life Sciences, Information Technologies and Industrial Technologies. Mission An expert team CDP Capital |
| Genzyme
Corp. Founded in 1981, Genzyme today is one of the largest
and most well established Genzyme-sponsored research and development has led to the introduction of new treatments for many serious health problems, from rare and debilitating genetic diseases to renal disease, orthopaedic injuries and the adverse effects of hypothyroidism. Building on more than two decades of growth and success, the company’s international R & D team and state-of-the art bioengineering and manufacturing facilities are continually at work identifying new opportunities to meet the health care challenges of the future. With headquarters in Cambridge, Massachusetts, Genzyme has approximately 5,500 employees working in 40 countries and annual revenues of more than $1 billion. Under the umbrella of Genzyme Corporation, the company is divided into three divisions, each representing a major focus of the health care market in research, product development, and patient care. |
| Harvard
Medical School Profile to follow shortly |
| HBM
Partners AG HBM BioVentures AG was founded in 2001 by Dr. Dr.
h.c. Henri B. Meier, the former CFO of Roche Holding AG and by the
management team. With capital under management in excess of 600
Mio Euro it is now one of the biggest investment vehicles in Europe
dedicated exclusively to life science investments. HBM BioVentures AG is exclusively advised by HBM
Partners. |
| HealthCare
Ventures, LLC HealthCare Ventures (“HCV”) is among the leading venture capital firms specializing in biotechnology and life science investing, making investments in early stage and emerging growth companies that have the potential for exceptional growth. HCV has started or invested in over 50 biotechnology-based health care companies, many of which have been pioneers in genomics, gene therapy, chemi-informatics, high-throughput drug screening, transplantation and other important fields. HealthCare Ventures VII, a $350 million fund, was raised in 2002. To date, HCV has over $1 billion under management. As it has since 1985, HCV will continue to create, finance, and manage biopharmaceutical companies. |
| Millennium
Pharmaceuticals Inc Profile to follow shortly |
| Merlin
Biosciences Merlin Biosciences is a specialised venture investor in life sciences companies. It makes equity investments on behalf of the investment partnerships that it manages. Since 1997, Merlin has invested in 21 European biotechnology companies. It is raising its third investment partnership, the Merlin Biosciences Fund III, L.P., and has a total of $500 million of equity capital under management. It has a world-wide, loyal network of advisers and experienced strategic partners. Merlin invests in companies that have ground-breaking technology and human medicines or devices with high commercial potential. It has a reputation as an attractive partner for management teams who can create substantial value for investors. |
| Novartis
Pharma AG Novartis (NYSE: NVS) is a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care, and animal health. In 2001, the Group's businesses achieved sales of CHF 32.0 billion (USD 19.1 billion) and a net income of CHF 7.0 billion (USD 4.2 billion). The Group invested approximately CHF 4.2 billion (USD 2.5 billion) in R&D. Headquartered in Basel, Switzerland, Novartis employs about 72 600 people and operates in over 140 countries around the world. For further information please consult www.novartis.com. |
| Oxford
BioScience Partners Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to start-up and early-stage, entrepreneurial-driven companies in the bioscience and healthcare industries. The General Partners of OBP currently manage venture funds with combined committed capital of more than $800 million. |
| Polaris
Venture Partners Polaris Venture Partners is an early stage venture capital firm with two locations in the U.S: Boston, Massachusetts, and Seattle, Washington. Polaris currently has over $2.0 billion under management with investments in more than 50 diversified information technology and medical technology companies. Through its philosophy of active lead investing and partnering with early and revenue stage companies, the firm’s team of experienced venture investors and technology executives has generated triple-digit returns from investments across its four funds. Polaris invests two-thirds of its capital in information technology and one-third in medical technology companies. Within the information technology sector, Polaris has invested in companies with expertise in Internet infrastructure, e-commerce, telephony, and network hardware and software. In the medical technology sector, the firm has invested in companies focused on medical devices, pharmaceuticals, genomics, and health care services. Polaris Venture Partners has more than 50 companies in its portfolio, including industry leaders such as Akamai Technologies, Allaire Corporation, Avici, decode Genetics, and Paradigm Genetics. Headquarters: 1000 Winter Street, Suite 3350 |
| Schroder
Ventures Life Schroder Ventures Life Sciences ("SVLS") was established in 1993 and currently has offices in Boston, London and San Francisco, which allows us to take advantage of the global nature of life sciences opportunities. The SVLS team is comprised of 24 professionals, with a deep base of life science investment, operational, scientific and clinical experience. SVLS advises three private equity funds with total commitments of approximately $640m, focused on providing seed, start-up, early stage and expansion capital to life sciences companies primarily in the US and Europe. In addition, SVLS advises the International Biotechnology Trust (IBT) plc, a publicly quoted investment trust listed on the London Stock Exchange (IBT), with a total net asset value of approximately $56m (as at 30 June 2002). The majority of IBT's investments are in quoted companies. Funds advised by SVLS are able to invest in all stages in the development of a life science business. SVLS provides hands-on scientific, advisory and financial support to its portfolio companies. |
| The
Sprout Group Founded in 1969, the Sprout Group raised its first venture fund of $12 million more than 30 years ago. Since then, Sprout has financed more than 350 companies whose combined revenues now exceed $50 billion and has raised nearly $3.5 billion in committed capital from leading institutional investors and individuals active in the technology industry. Sprout Group has helped to establish such well-known names as Actel, Advanced Micro Devices (AMD), Cephalon, Corporate Express, Deltagen, mySimon, Pyxis, SDL, Spotfire, Staples, StrataCom, and VeriFone. In November 2000, Sprout closed Sprout IX, a fund totaling $1.6 billion. We are actively investing Sprout IX in communications, software, and healthcare technology companies at all stages of development from start-up through buyout. While we are not typically providers of seed capital, our fund size does not preclude early stage investing. Sprout IX is capitalized primarily by commitments from large corporate and public sector pension funds, insurance companies, endowments, and other private investors - most of whom have invested in previous Sprout funds. Our roster of limited partners includes AIG, AXA, Brinson Partners, The Common Fund, Equitable Life, and Toronto Dominion Bank, as well as pension funds of BP (ARCO), BellSouth, Stichting, and the states of Michigan, Colorado and Washington. The Sprout Group is a venture capital affiliate of Credit Suisse First Boston, a leading technology investment bank. Our Investment Philosophy As members of the Board and its key committees,
Sprout professionals are active participants in our portfolio companies'
major strategic, operational, and financial decisions without becoming
a part of the operating management. Specifically, we frequently
assist our portfolio companies in recruiting, business strategy,
financing strategy and mergers and acquisitions. Sprout's Venture
Partners often help in supplementing management by participating
in strategic or operational projects for our companies. Prior investments that are no longer in Sprout's portfolio are designated by an *. The companies below do not represent a complete list of all of Sprout's current and historical portfolio company investments. Healthcare Technology:
Biopharmaceuticals, Drug Discovery Technology, Healthcare Information
Technology, Medical Products |
| Techno
Venture Management Techno Venture Management (TVM), founded in 1983, is one of the first venture capital funds formed in Germany, and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth. TVM funds have made investments in 200 technology companies in Europe and the United States. A pivotal objective is to create transnational businesses that enjoy access to science, management talent and capital on both sides of the Atlantic. |
| Warburg
Pincus LLC Warburg Pincus LLC is a leading venture capital and private equity firm headquartered in New York. The firm is currently investing its eighth fund, Warburg Pincus Private Equity VIII, which had a final closing in April 2002 at $5.3 billion. Warburg Pincus has been a leading sponsor of biotechnology and pharmaceutical companies since it began focusing on the industry in 1981. The firm has invested more than $800 million in over 35 companies spanning a broad range of technologies and stages of development. The common themes in these investments are leading scientists and outstanding management teams, innovative science within the context of sound business models, and opportunities to provide important health care solutions. The firm’s goal is to build world-class companies by partnering with top entrepreneurs. Examples of some recent investments by Warburg Pincus include InterMune Pharmaceuticals, The Medicines Company, Triangle Pharmaceuticals, Visible Genetics, ZymoGenetics, Sunesis Pharmaceuticals, and Synaptic Pharmaceutical. |
| Zero
Stage Capital Founded in 1981, Zero Stage Capital is a venture capital firm that invests in emerging growth companies in the following technology sectors: information technology, communications, life sciences and energy technology. Zero Stage Capital is headquartered in Cambridge, MA and has offices in Manchester, NH, New Haven, CT and Providence, RI and primarily invests in companies located along the east coast of the United States. One of the original pioneers of start-up company investing, Zero Stage Capital proactively invests and manages a balanced and diversified fund investing across technology sectors and across all stages of company growth. Zero Stage Capital seeks to achieve superior returns for its investors, while creating an attractive liquidity profile, by investing approximately 50 percent of its funds in early-stage ventures and 50 percent in later-stage ongoing companies. Since 1994, Zero Stage Capital has performed in the top ten percent among peer funds. With more than 140 years of venture capital, entrepreneurial, operating, and industry experience among its investment professionals, Zero Stage Capital is the lead investor in more than 80 percent of its portfolio company investments. |